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Abstract
The current outbreak of COVID-19 pandemic traces its roots back many decades
and is worsened by a number of ill-conceived strategies and policies. The current
patent protection regime and its suitability in dealing with the current COVID-19
pandemic need to be questioned. Strengthened intellectual property protection
manifested by the rise of TRIPS-Plus standards is having a negative impact on
the affordability and accessibility of medicines. Dealing with the current













2020 has been an eventful year for what we know. Marked by the so far
unstoppable outbreak of the Coronavirus (COVID-19) pandemic, the year will also
be remembered for the newly adopted wealth of vocabulary. ‘Social and physical
distancing’, ‘shielding’, ‘testing’, ‘vaccine wars’, ‘self-isolating’, ‘pandemic’,
‘quarantine’, ‘lockdowns and curfews’, ‘covidiots’, ‘herd immunity’ and ‘key
workers’ are few examples. Although the usage of these expressions within the
current circumstances is new, no one can claim that the threat of a serious disease
developing into a pandemic was not envisioned, even in the recent past. In fact,
what is rather interesting is that this has not taken place much earlier, considering
that the last global pandemic which humankind had to face took place over a
hundred years ago (the 1918 influenza pandemic known as the Spanish flu) and
noting that during the past few decades we have had to deal with the outbreak of a
number of troubling diseases such as Ebola, SARS-CoV and H1N1 which all had
the potential to become pandemics as well.
Looking at the current situation from this perspective, the question which often
arises is how did we get to this stage in today’s world despite all the progress made
in so many fields specially in terms of innovation, development, medical and
technological health advances? Did we simply ignore the signs or, to the contrary,
adopted policies and strategies which exacerbated this situation throughout the
years?
This article will argue that the policies advocated and adopted by many during the
past decades have curtailed our ability to deal with the current situation efficiently.
Higher levels of intellectual property rights (IPRs), lack of innovation and R&D for
treatment in certain diseases and technologies, and our inability to learn from
previous experiences have made the current situation extremely difficult and
potentially untenable at least in the short term. These factors have led to higher
prices of medicines and lack of affordability and accessibility to treatment hence
making a larger segment of society more susceptible to the current virus, and as a
result placing additional constraints on governments and individuals alike. In
addition, it is acknowledged that the far-reaching measures taken to combat the
pandemic will have a massive impact on human rights and the implementation of
the internationally agreed Sustainable Development Goals (SDGs).  As such,
radical thinking is needed in order to deal with these unprecedented circumstances
before it is too late.




The price of medicines has been on a steady increase for some time. In the US,
prices for branded prescription drugs doubled in 5 years between the period of
2011–2016.  Further, it was projected that the prices of medicines in the US will
increase on average 5.8% in 2020.  A recent study in the UK found that total
National Health Service (NHS) spending on medicines in England has grown from
GB£13 billion in 2010/11 to GB£17.4 billion in 2016/17—an average growth of
around 5% a year (Ewbank et al. 2018).
Medicines costing millions of dollars in not unheard news in today’s world. In
March 2019, the United States Food and Drug Administration (USFDA) approved
the most expensive medicine in history called Zolgensma (priced at US$2.125
million), a medicine used for a rare disorder that destroys a baby’s muscle control
and kills nearly all of those with the most common type of the disease within a
couple of years. Newly developed hepatitis C drugs’ prices have also been set out
of the reach of the majority in both low-income and high-income countries.
The effects of this scenario are being felt globally. Greater number of patients are
now unable to afford medicines while governmental health budgets are struggling
to cater for the needs of their citizens. Even worse within the context of the current
pandemic, it is established that those who have a serious premedical condition are
more vulnerable. A recent study by the Lancet found that one in five people
worldwide are vulnerable to severe COVID-19 due to chronic health conditions
(Clark et al. 2020). As such, the current accessibility to medicines dilemma coupled
with the ongoing global crises can only deepen these wounds further unless speedy
and logical solutions are implemented.
Now and Then: Lessons from History for the Future
Governments are under extreme pressure to manage the current situation and its
ramifications at both the domestic and international levels.  Demonstrations and
protests are taking place regularly in several European and US cities channelling
different lines of collective concerns. Some are directed towards governments’
inability to control the diseases and save the lives of many, while others give voice
to the growing anger about the extreme measures taken to deal with and control the
spread of the disease.  Meanwhile, many protests in the US are taking place as part
of the Black Lives Matter movement, revealing the need for a systemic review of
institutional violence and discrimination (Buchanan et al. 2020).
As the wait for a vaccine or effective treatment of COVID-19 continues, attempts
are made in order to reassure the population that all necessary measures are taken
by stockpiling and pre-ordering of vaccines, despite the fact that previous
experiences have shown the inadequacy of this approach and its culmination in the









announced that the United Kingdom would secure 90 million doses of two
promising COVID-19 vaccine candidates, joining a growing group of rich
countries. This resembles the previously failed attempt in dealing in the case of
H1N1 back in 2002, whereby government agencies in the EU and US (in addition to
WHO’s initial supportive stance at the time) recommended the use of Oseltamivir
(Tamiflu), a neuraminidase inhibitor,  for treatment and prophylaxis of influenza,
and its stockpiling as a measure to tide over the crisis that time, despite the fact that
no scientifically robust data on efficacy and safety of the drug was available. Even
worse, serious adverse cases, especially neuropsychiatric events associated with
Tamiflu, started getting reported leading to a cascade of questions on the clinical
utility of this particular drug (Gupta et al. 2015).
Finally, in 2014, the Cochrane Review findings concluded that there were small
benefits on symptom relief, namely shortening duration of symptoms by half a day
on average. In general, however, there is little evidence to support any belief that
use of neuraminidase inhibitors (NIs) such as Tamiflu reduces hospital admission or
the risk of developing confirmed pneumonia. The evidence also suggests that there
are insufficient grounds to support the use of NIs in preventing the person-to-person
spread of influenza (Jefferson et al. 2014).
Unfortunately, as highlighted, it appears that some governments are repeating the
same scenario which may further result in more ‘costly mistakes’ at a time where
resources are stretched further. More worryingly, health experts and access
advocates warn that this approach may in fact leave ‘poorer countries in the lurch
as states scramble to pre-order doses while COVID-19 vaccine candidates enter late
stage clinical trials’ (Ren 2020). Access to medicines advocates decried the move,
accusing the UK of fuelling ‘vaccine nationalism’ and joining other rich countries
to ‘hoard’ the vaccine before it even hits the market (Ren 2020).
Unfortunately, a similar scenario is also taking place with remdesivir– an antiviral
that was shown to reduce hospitalization times for COVID-19 patients-, one of the
few promising treatments currently used in the fight against COVID-19. In early
July 2020, it was announced that the US had secured almost all of Gilead Sciences’
projected production of remdesivir for the next three months. The US Health and
Human Services (HHS) stated in a press release that it secured 100% of Gilead’s
projected production for July (94,200 treatment courses), 90% of production in
August (174,900 treatment courses), and 90% of production in September (232,800
treatment courses), in addition to an allocation for clinical trials.  Although the
motives of the US administration behind such a decision are clear, the moral and
ethical questions which are raised in this regard are also very evident. How are
other countries supposed to access remdesivir, particularly in the absence of the
availability of the treatment and in the situation of lack of licensing by the





Gilead’s license would have to buy from Gilead, but they can’t buy from Gilead
because the United States and Europe have bought up the entirety of Gilead’s
supply,’ (Vijay 2020) Gilead will have only 15,300 treatment courses available for
countries outside the EU and US to access from August to September (Rizvi 2020).
These examples show how little was learnt from previous experiences. They also
reflect a clear lack of understanding about the current priorities. More worryingly
and contrary to public understanding, is the fact that governmental regulatory food
and drug authorities may not fully get things right all the time as the Cochrane
Review demonstrated.
IPRs and the Rise of TRIPS-Plus world
As often been acknowledged, intellectual property protection has a direct negative
impact on the affordability and availability of medicines and medical technologies.
Within the current debate, intellectual property is both seen and used as a sword and
a shield at the same time.
Historically, developed countries have pushed for the strengthening of IP protection
due to their status as net importers of IP-related goods and services (Sell 2003). The
aggressive push resulted in the creation of the Agreement on Trade-Related Aspects
of Intellectual Property (TRIPS Agreement) in 1995,  thus creating for the first
time a binding and comprehensive international agreement covering the majority of
IP rights. The Agreement dictates that patent protection is awarded to all types of
inventions including those related to pharmaceutical patents. Although many
policymakers in developed countries were convinced that TRIPS would put an end
for the ‘ratching up’ of IP protection levels globally, the outcome was to the
contrary. Within less than a decade from the birth of the TRIPS Agreement, the
proliferation of free trade (FTAs) and bilateral investment (BITs) agreements
containing heavy IP obligations which go beyond those prescribed under the TRIPS
Agreement became the norm. These agreements setting higher levels of IP
protection are commonly referred to as ‘TRIPS-Plus’ agreements (El Said 2005).
In simple terms, TRIPS-Plus rules restrict countries’ freedom and ability to utilise
available policy space and direction when designing and implementing their
national IP protection regime by incorporating extensive protection levels which go
beyond those incorporated under the TRIPS Agreement. This approach is
championed by the EU and US and has taken an ‘upward’ trend over the time,
whereby more and more obligations were added to each subsequent agreement
signed.
In order to understand how TRIPS-Plus conditions erode policy space within the
patent regime, an explanation of the meaning of TRIPS flexibilities (and their




Agreement adopts a ‘minimum standards’ of protection approach, which means that
all WTO member states will have to provide the minimum ceilings of protection as
prescribed under the TRIPS Agreement under their national laws, while at the same
time are free to raise the levels above those if they deemed so in accordance with
their national priorities and development stages and subject to respecting the Most
Favoured Nation (MFN) and National Treatment (NT) principles. This approach
provided member states with a reasonable policy space and flexibility in some
respect about how to incorporate and define the ‘minimum standards’ under their
national legislations and legal regimes. The following are some examples of these
flexibilities with selected examples about the positive impact their use had on the
accessibility and affordability of medicines.
• Transition periods Least developed countries (LDCs) were granted an extended
transition period exempting them from protecting intellectual property as stated
under the WTO’s TRIPS Agreement. This is in recognition of their special
developmental needs and the balance that should be put in place prior to the
introduction of intellectual property protection under their national law. More
recently, several extensions of the transition period were provided by the
TRIPS Council.  This means LDCs can choose not to provide legal protection
for pharmaceutical patents and clinical trial data before 2033. The decision also
keeps open the option for further extensions beyond that date.  A number of
low-income countries—Uganda, Cambodia and Rwanda for example- have
already benefited from this flexibility hence ended up using the full transition
period granted to them.
• Compulsory licensing It allows the state to authorize a third party to exploit
patented inventions, generally against a specific remuneration to be paid to the
patent holder subject to meeting several conditions (Article 31 of the TRIPS
Agreement). The aim of compulsory licensing authorization is to limit anti-
competitive behaviour and facilitate the transfer of technology.  This tool has
proven its effectiveness in a number of cases in terms of dealing with national
health priorities by reducing prices of medicines substantially where a national
production capability exist. For instance, the Ecuadorian Institute of
Intellectual Property (IEPI) reported that between 2013 to 2017 it issued ten
compulsory licences for various medications including antiretroviral drugs.
According to health officials in Ecuador, the compulsory licenses granted
between 2013 and 2014, generated the potential for savings of 23% to 99%
(Correa and Velásquez 2019). Similar reductions were also achieved in the case
of other compulsory licenses issued by Thailand, India, Indonesia, Brazil and
Columbia (El Said 2016). Despite this, it should be noted that the process of
issuing a compulsory license is often marred by bureaucratic requirements and









• Government use exceptions This flexibility gives the state the right to use the
patent without the need to acquire the approval of the patent holder for the
purpose of public interest, including public health necessities and emergencies.
Although there are similarities between the conditions needed to issue a
government use and compulsory licensing, government use exceptions provide
an additional advantage by allowing the license to be issued in a speedy
manner, through granting the government the right to use the pharmaceutical
patent without the need for prior negotiations with the owner. Positive
examples of using this flexibility are many. For instance, in 2017 Malaysia
issued a ‘government use’ compulsory license to obtain a cheaper generic
version of the widely known hepatitis C medicine Sofosbuvir. It is believed
that this compulsory license has enabled a cheaper treatment cost to be between
RM 1000 to RM 1200 (US$ 240-US$ 285) for 12 weeks course, compared to
RM 300,000 (approx. US$ 72,000) which was the cost of treatment with the
patented version prior to issuance of the license (Ling 2019).
• Parallel importation This flexibility grants countries the option to obtain
patented products when they are lawfully available in a foreign market at a
lower price, thus enabling countries to shop for cheaper patented products.
For example, Kenya has actively and effectively used parallel importation to
improve access to antiretroviral medications.
• Exceptions to patents rights Article 30 of TRIPS provides that members ‘may
provide limited exceptions to the exclusive rights conferred by a patent,
provided that such exceptions do not unreasonably conflict with a normal
exploitation of the patent and do not unreasonably prejudice the legitimate
interests of the patent owner, taking account of the legitimate interests of third
parties’.  However, the above provision does not define the scope of the
permissible exceptions thus awarding member countries some considerable
discretion to operate. Examples of these exceptions include the Bolar
exception,  personal use and the research and experimental use exceptions.
• Standards of patentability Under TRIPS, patent protection must be granted for
products and processes which are new, involve an inventive step and are
industrially applicable.  These are not defined and can be interpreted and
applied by member states in accordance with their national legal regimes. For
example, TRIPS does not require countries to protect the patenting of new uses
of known products, including pharmaceutical drugs. This flexibility therefore
allows member countries the possibility of rejecting the patentability of these
new uses for lack of novelty, inventive step or industrial applicability. The case








patentability criteria aimed towards limiting the number of frivolous or
secondary pharmaceutical patents granted are applied (Chatterjee 2013). This
has the effect of limiting patent abuse cases by not granting of low-quality
patents (anti-evergreening strategy).  Egypt is also applying similar vigorous
examination practises. The country is home to the highest rate of hepatitis C
infections in the world. A couple of years ago the Egyptian’s Patent Office
rejected one of Sofosbuvir patent applications through resorting to strict
patentability criteria. This allowed a local generic manufacturer to produce the
drug for less than US$ 200 per twelve-week treatment.
• Other procedural flexibilities Another identified policy tool used by low-
income and high-income countries to improve the quality of granted patents
and limits ‘evergreening’ is pre-grant and post-grant patent oppositions, in
addition to patent revocation proceedings. Such proceedings enable interested
parties to bring claims before the patent office on the basis that a particular
patent does not meet local requirements. Opposition procedures have been
applied usefully and efficiently in several countries.  This is an important
procedure due to the fact that it is believed that current estimates suggest that
at least 27% of current patents would be found invalid by US courts due to low
quality (Miller 2012).
As highlighted earlier, recent FTAs containing TRIPS-Plus standards of protection
have targeted precisely the above examined flexibilities during the past two decades
resulting in the erosion of policy space and diminishing of flexibilities usage in
many countries.  As such, the following are some examples of these TRIPS-Plus
standards supported by some selected examples about their negative impact on
access to medicines.
Expanding and extending the scope of pharmaceutical patents and creating new
drug monopolies: this is achieved through lowering the patentability standards and
allowing for new and second use patenting in addition to vaccines and gene
patenting and prolonging the patent protection term. A study by Amin and
Keselheim on the impact of ‘evergreening’ resulting from the granting of secondary
patents concluded that secondary patents could extend market exclusivity for many
years. The study identified 108 patents related to two HIV medicines (ritonavir
(Norvir) and lopinavir/ritonavir (Kaletra)) whose impact could delay generic
competition until at least 2028. This is a twelve years additional period after the
expiration of the patents on the drugs’ base compounds and thirty-nine years after
the first patents on ritonavir were filed (Amin and Kesselheim 2012: 2286).
• Protection and Extension of ‘data exclusivity’ and patent linkage: by requiring
protection of at least 5 years exclusivity for information related to new






information is disclosed and available in the public domain.  Another TRIPS-
Plus requirement is the linking of the status of patent grant with marketing
approval. A 2007 Oxfam study on the effect of the US-Jordan FTA found that
since 2001 the prices of medicines in Jordan have increased by 20% (this led to
price soaring between two and ten-fold for key medicines to treat
cardiovascular disease and cancer), and data protection provisions have
resulted in delaying generic drugs entry for 79% of medicines newly launched
between the years 2002 and 2006 (Oxfam 2007).
• Prohibition/restriction pre-grant oppositions: These restrictions forbid
challenges to weak or invalid patents until after they have been granted. As
highlighted above this is a real dilemma is we take into consideration the
estimates suggesting that at least 27% of current patents would be found
invalid by US courts due to their low quality (Miller 2012: 28).
• Requiring new forms of intellectual property enforcement These requests
include claims related to customs detaining shipments, including in-transit
shipments, suspected of non-criminal trademark/copyright/patent
infringements; require mandatory injunctions for alleged intellectual property
infringements; raise damages amounts…etc.
Introducing Investor-State Dispute Settlement (ISDS) procedures This highly
controversial aspect of the FTAs and BITs grants private investors, especially big
multinational corporations, considerable power to claim huge amounts
compensation from investor sympathetic tribunals in case where governments take
certain measures which may be considered from the perspective of an investor as
expropriation, discriminatory or breaches other general substantive standards or
protection in that state. This question the impact of these claims on states’ power to
regulate in the public interest, in order to safeguard public health priorities and
challenges. An example of this controversial aspect was demonstrated in the Philip
Morris Asia versus Australia  case whereby the Australian Federal Government
passed the Tobacco Plain Packaging (TPP) Act in 2011 requiring restrictions on the
use of advertisements of tobacco and the increase of the size of the graphic health
warnings on the front face of the pack from 30 to 75% based on public health
considerations. This decision was challenged by the tobacco industry alleging that
the measures amounts to expropriation and interferes with their trademarks rights in
Australia and breaches international IP- investment- and trade law under the
bilateral investment treaty (BIT) between Hong Kong and Australia (HK—AUS
BIT). They unsuccessfully demanded the suspension of the measures and
compensation amounting to billions of dollars  Other flaws of the ISDS system
include the lack of consistency in decision making and huge costs. There is now
growing evidence that the threat of using these ISDS procedure is enough to







The effect of these TRIPS-Plus standards has been acknowledged by many in recent
times resulting in even higher medicines prices and longer monopoly term all at the
expense of patients and citizens particularly in low-income countries. (El Said,
2010). This issue should not be seen in isolation of the current crises facing many
across the globe. This is the case specially since those ‘vulnerable’ segments of
society are more susceptible to have severe COVID-19 infections or higher
mortality rates. In fact, according to a recent World Bank study it is believed that
the share of low-income countries in global fatalities from COVID-19 could be
three times higher than other countries (Schellekens and Sourrouille 2020). As such
and since many of those vulnerable patients could not afford basic treatment in
many cases due to high prices and patent monopolies, it is believed that the current
outbreak can only drive them more in despair.
IP Protection in the Times of COVID-19
Many measures have been desperately taken by governments with the aim of
containing the spread of the current outbreak, from curfews to lockdowns, social
distancing and shielding. Despite the fact that global calls for solidarity have been
made by many including the United Nations, the World Health Organization
(WHO), the World Bank and the WTO in order to deal with the crisis,  we have
also witnessed some resistance by IP holders aimed at protecting their proprietary
rights.
In recognition of IP’s ability to restrict the accessibility and production of certain
medical and diagnostic products and goods, governments have taken several
intellectual property-related measures in order to deal with the current situation and
overcome the barriers created by the IP regime.
The need to urgently secure essential products including medicines, personal
protective equipment, testing kits, CT scanners, and ventilators has been identified
as a priority by many countries from the beginning of the pandemic leading some to
even ban their exportation (Boykoff 2020). Furthermore, several low-come and
high-income countries have already taken concrete steps in order to facilitate access
to medications and medical equipment through limiting or removing any
intellectual property restrictions in this regard by issuing compulsory licenses and
government use authorizations. For instance, on 17 March 2020 the Parliament of
Chile adopted Resolution No. 896 declaring that the global coronavirus outbreak
justifies the use of compulsory licensing to facilitate access to vaccines, drugs,
diagnostics, devices, supplies, and other technologies useful for the surveillance,
prevention, detection, diagnosis and treatment of the coronavirus in Chile (Syam
2020: 2-3). Israel took similar measures by issuing a government use authorization
under the Israeli patent law for the importation of generic lopinavir/ritonavir






Indian generic company by a local company acting on behalf of the Israeli ministry
of health because AbbVie was unable to provide sufficient supplies of
lopinavir/ritonavir (Syam 2020: 3). AbbVie has announced that it will not enforce
its patent in light of the current pandemic.
The use of competition law has often been recognized as an important tool in the
process of curtailing IP abuse. More recently, the European Commission (EC)
launched a preliminary investigation on the abuse of the dominant position in the
Dutch market by the Swiss multinational pharmaceutical company Roche, on
account of its reported refusal to share the secret formula for producing a buffer
solution that is necessary for use in testing kits for COVID-19. This has lead Roche
to immediately announce that it will release the recipe for its lysis buffer if Dutch
laboratories ask for it (Van Ark and Strop 2020). The EC has also stated that during
the pandemic it will continue to closely and actively monitor relevant market
developments to detect instances of potential activities that may take advantage of
the current situation to breach European Union competition law and policy, by
either engaging in anti-competitive agreements or abusing their dominant
position.
Moreover, on 23 March 2020, France enacted a new law No. 2020-290 which
introduced one (Art. L.3131-15) to the country’s public health law allowing the
French Prime Minister to order the seizure of all goods and services necessary to
fight against sanitary disaster; to temporarily control the prices of products; and to
take any measures necessary to make relevant medicines available to patients
(Syam 2020: 3).
The above are few examples of the measures targeting the intellectual property
rights within the current COVID-19 context. These national initiatives represent a
patent acknowledgement that such rights need to be restricted and limited otherwise
the damage to society would be greater than the benefits of protection.
Conclusion
The current COVID-19 outbreak represents one of the gravest challenges
humankind has had to deal with during the last 70 years or so. The politicization of
this crisis and making decisions based on business and political considerations
instead of public health concerns is a real threat and can only prolong the suffering
of many.  This situation requires unconventional strategies and polices. It demands
a serious breakout from the prevailing traditional way of thinking which dictated
our approach in dealing with international economic and trading relations since the
1950s. We must start to critically question the existing policies and their failure and
proactively seek a new and more inclusive approach in dealing with these trade and






The starting point in this debate is the acknowledgment that we have a flawed
global patent regime in place in need of a desperate and urgent reform. Of course, it
should be made clear that the current regime is not the only reason for our
challenges and other factors should also be equally dealt with including inadequate
R&D levels, procurement policies, tax reform, judicial reform and so forth. Calls
for the need of a reformed patent regime are not new. However, the systemic
conflict between strengthened patent protection and public health needs and
challenges is rising and this explains why some of the high-income countries are
often the first to initiate restrictions and impose limitations on the intellectual
property regime during public health crises, such as the one we are currently facing.
There is also an urgent need to put an end to the strengthening of intellectual
property protection levels globally. The rise of TRIPS-Plus standards through
various agreements and arrangements have had grave repercussions on the needy
everywhere and is likely to get worse unless something serious is done about it. A
fundamental aspect of this would be to remind ourselves about the public goods
nature of health care provision and the need to make decisions departing from this
perspective, not business or political considerations. Including TRIPS-Plus
standards in new agreements should no longer be allowed, while previously agreed
TRIPS-Plus provisions will need to be abolished. Concurrently, governments,
health activists and policy makers should start the debate about reforming the
TRIPS Agreement and the impact of the patent regime on access to medicines and
public health.
The strengthening of the current medical R&D system is vital as well for both
dealing with the current outbreak and other diseases affecting many. The IP regime
cannot continue to be used as the main mechanism to compensate innovators but
should also be supplemented by other tools. Targeted government funding
programmes, prizes schemes, shared pooling arrangements and reward strategies
should gain more recognition in this process (Suleman et al. 2020). As importantly,
is the need to make available and declare all new vaccines and treatment to
COVID-19 as a global public good. Emerging calls such as the one made by Costa
Rica in March 2020 for the creation of a global pooling mechanism in order to
facilitate access to and use of intellectual property, trade-secret know-how,
regulatory data, and other proprietary data for technologies that are useful for the
detection, prevention, control, and treatment of the COVID-19 pandemic must be
given the attention they deserve, if the world is serious about accelerating R&D.
Finally, transparency in drug pricing is pivotal to ensure that fair compensation is
granted to those who invest in finding medical solutions to diseases, and affordable
drug prices are applied so that patients can afford them. The 2019 World Health
Assembly’s resolution supporting greater public disclosure of prices for medicines




Governments and key international organizations need to promptly capitalize on the
current crisis and the opportunities it offers in terms of reforming many of the ill-
conceived policies of the past. The solution to today’s health emergency is clear; a
universal holistic solution whereby all efforts are united and channelled towards
finding a vaccine and enhancing treatment to COVID-19 is needed rather a national
one. Countries can take whatever national measures available at their disposal
including lockdowns, curfews and further travel restrictions…etc. Yet, if this
challenge is not dealt with collectively and at a global scale, then COVID-19 is
likely to stay with us—with all its damaging human, economic, financial and
psychological consequences—for a long period of time.
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